These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19289118)

  • 41. Allele-specific silencing of the gain-of-function mutation in Huntington's disease using CRISPR/Cas9.
    Shin JW; Hong EP; Park SS; Choi DE; Seong IS; Whittaker MN; Kleinstiver BP; Chen RZ; Lee JM
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040815
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gene therapy for Huntington's disease.
    Ramaswamy S; Kordower JH
    Neurobiol Dis; 2012 Nov; 48(2):243-54. PubMed ID: 22222669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Huntington's disease: the current state of research with peripheral tissues.
    Sassone J; Colciago C; Cislaghi G; Silani V; Ciammola A
    Exp Neurol; 2009 Oct; 219(2):385-97. PubMed ID: 19460373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.
    Hu J; Matsui M; Corey DR
    Ann N Y Acad Sci; 2009 Sep; 1175():24-31. PubMed ID: 19796074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence.
    Benyamina A; Bonhomme-Faivre L; Picard V; Sabbagh A; Richard D; Blecha L; Rahioui H; Karila L; Lukasiewicz M; Farinotti R; Picard V; Marill C; Reynaud M
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1270-4. PubMed ID: 19625010
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Downregulation of Janus kinase 3 expression by small interfering RNA in rat composite tissue allotransplantation.
    Chang KP; Lai CH; Huang SH; Tai HT; Chang LL; Lin SD; Hwang SL; Lai CS
    Transpl Immunol; 2009 May; 21(1):27-32. PubMed ID: 19233270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis.
    Camiña-Tato M; Morcillo-Suárez C; Navarro A; Fernández M; Horga A; Montalban X; Comabella M
    J Neuroimmunol; 2009 Aug; 213(1-2):142-7. PubMed ID: 19515430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved adapter-ligation-mediated allele-specific amplification for multiplex genotyping by using software.
    Wang W; Sun W; Wu W; Zhou G
    Electrophoresis; 2008 Apr; 29(7):1490-501. PubMed ID: 18318448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Huntington's disease mortality in Spain in the period 1981-2004].
    Ramalle-Gomara E; Gonzalez MA; Perucha M; Quinones C; Lezaun ME; Posada-De la Paz M
    Rev Neurol; 2007 Jul 16-31; 45(2):88-90. PubMed ID: 17642048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Darwinian approach to Huntington's disease: subtle health benefits of a neurological disorder.
    Eskenazi BR; Wilson-Rich NS; Starks PT
    Med Hypotheses; 2007; 69(6):1183-9. PubMed ID: 17689877
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proof concept for clinical justification of network mapping for personalized cancer therapeutics.
    Nemunaitis J; Senzer N; Khalil I; Shen Y; Kumar P; Tong A; Kuhn J; Lamont J; Nemunaitis M; Rao D; Zhang YA; Zhou Y; Vorhies J; Maples P; Hill C; Shanahan D
    Cancer Gene Ther; 2007 Aug; 14(8):686-95. PubMed ID: 17541424
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease.
    Bečanović K; Nørremølle A; Neal SJ; Kay C; Collins JA; Arenillas D; Lilja T; Gaudenzi G; Manoharan S; Doty CN; Beck J; Lahiri N; Portales-Casamar E; Warby SC; Connolly C; De Souza RA; ; Tabrizi SJ; Hermanson O; Langbehn DR; Hayden MR; Wasserman WW; Leavitt BR
    Nat Neurosci; 2015 Jun; 18(6):807-16. PubMed ID: 25938884
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Usage of mitochondrial D-loop variation to predict risk for Huntington disease.
    Mousavizadeh K; Rajabi P; Alaee M; Dadgar S; Houshmand M
    Mitochondrial DNA; 2015 Aug; 26(4):579-82. PubMed ID: 24471944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting siRNA to arrest fibrosis.
    Friedman SL
    Nat Biotechnol; 2008 Apr; 26(4):399-400. PubMed ID: 18392021
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome.
    Dekker MJ; van den Akker EL; Koper JW; Manenschijn L; Geleijns K; Ruts L; van Rijs W; Tio-Gillen AP; van Doorn PA; Lamberts SW; Jacobs BC
    J Peripher Nerv Syst; 2009 Jun; 14(2):75-83. PubMed ID: 19691529
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen class II alleles in chronic fatigue syndrome: are they associated with age at onset and specific symptoms?
    Ortega-Hernandez OD; Cuccia M; Bozzini S; Bassi N; Moscavitch S; Diaz-Gallo LM; Blank M; Agmon-Levin N; Shoenfeld Y
    Ann N Y Acad Sci; 2009 Sep; 1173():589-99. PubMed ID: 19758204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules.
    Herringson TP; Altin JG
    J Control Release; 2009 Nov; 139(3):229-38. PubMed ID: 19595724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Allele variants in functional MicroRNA target sites of the neurotrophin-3 receptor gene (NTRK3) as susceptibility factors for anxiety disorders.
    Muiños-Gimeno M; Guidi M; Kagerbauer B; Martín-Santos R; Navinés R; Alonso P; Menchón JM; Gratacòs M; Estivill X; Espinosa-Parrilla Y
    Hum Mutat; 2009 Jul; 30(7):1062-71. PubMed ID: 19370765
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer.
    Muñoz-Guerra MF; Fernández-Contreras ME; Moreno AL; Martín ID; Herráez B; Gamallo C
    Ann Surg Oncol; 2009 Aug; 16(8):2351-8. PubMed ID: 19449077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.